These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16160166)

  • 21. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.
    Black PL; Downs MB; Lewis MG; Ussery MA; Dreyer GB; Petteway SR; Lambert DM
    Antimicrob Agents Chemother; 1993 Jan; 37(1):71-7. PubMed ID: 8381640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.
    Matsumi S; Matsushita S; Yoshimura K; Javaherian K; Takatsuki K
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):501-8. PubMed ID: 7632464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
    Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF
    PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
    J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
    Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
    mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).
    Belanger JM; Raviv Y; Viard M; de la Cruz MJ; Nagashima K; Blumenthal R
    Virology; 2011 Aug; 417(1):221-8. PubMed ID: 21726886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    Sattentau QJ; Moore JP; Vignaux F; Traincard F; Poignard P
    J Virol; 1993 Dec; 67(12):7383-93. PubMed ID: 7693970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
    Chertova E; Bess JW; Crise BJ; Sowder II RC; Schaden TM; Hilburn JM; Hoxie JA; Benveniste RE; Lifson JD; Henderson LE; Arthur LO
    J Virol; 2002 Jun; 76(11):5315-25. PubMed ID: 11991960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    Cole KS; Rowles JL; Jagerski BA; Murphey-Corb M; Unangst T; Clements JE; Robinson J; Wyand MS; Desrosiers RC; Montelaro RC
    J Virol; 1997 Jul; 71(7):5069-79. PubMed ID: 9188572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies against human immunodeficiency virus (HIV) type 2 core proteins: cross-reactivity with HIV type 1 and simian immunodeficiency virus.
    Minassian AA; Kalyanaraman VS; Gallo RC; Popovic M
    Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6939-43. PubMed ID: 2457921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.
    Fan YC; Chiu HC; Chen LK; Chang GJ; Chiou SS
    PLoS Negl Trop Dis; 2015 Oct; 9(10):e0004167. PubMed ID: 26495991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
    J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
    Kent KA; Rud E; Corcoran T; Powell C; Thiriart C; Collignon C; Stott EJ
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1147-51. PubMed ID: 1380261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.
    Termini JM; Church ES; Silver ZA; Haslam SM; Dell A; Desrosiers RC
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins.
    Berlioz-Torrent C; Shacklett BL; Erdtmann L; Delamarre L; Bouchaert I; Sonigo P; Dokhelar MC; Benarous R
    J Virol; 1999 Feb; 73(2):1350-61. PubMed ID: 9882340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys.
    Müller S; Margolin DH; Min G
    Hybridoma; 1997 Feb; 16(1):17-21. PubMed ID: 9085123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.
    Shafferman A; Jahrling PB; Benveniste RE; Lewis MG; Phipps TJ; Eden-McCutchan F; Sadoff J; Eddy GA; Burke DS
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7126-30. PubMed ID: 1871125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.